AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02095808 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Biomarkers
Description: Want to see if using 13C-glucose helps in detecting cancer and deciding on a treatment plan.
Study NCT02255825 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Whole Genome Sequencing
Description: Whole genome sequencing in a CLIA lab and return of results.
Study NCT02255825 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniocentesis
Description: Note: this is being performed on all subjects as a clinical (not research) procedure
Study NCT02255825 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniocentesis
Description: Note: this is being performed on all subjects as a clinical (not research) procedure
Study NCT02255825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial assessment
Description: Use of EPDS and STAI for assessment of maternal and paternal mood
Study NCT02255825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosocial assessment
Description: Use of EPDS and STAI for assessment of maternal and paternal mood
Study NCT03823014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elator
Description: Measurement for device, use of device
Study NCT04158700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200882
Description: LY3200882 administered orally
Study NCT04158700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered IV
Study NCT03370809 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brain PET/CT step
Description: a cerebral PET/CT will be registered on the 45th minute after 18F-FDG injection and just before the whole body recording. This recording does'nt need a new injection but needs a low dose scanner
Study NCT02038907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Hepatitis A Vaccine IM injection
Study NCT01323985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698
Description: IV (in the vein) single dose over 24 hours, in two sessions
Study NCT01408277 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Santyl
Description: 2 mm Santyl applied once daily
Study NCT01408277 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard Care
Study NCT03943576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GXCPC1
Description: The dose regimen is one single intra-articular injection of GXCPC1 containing 6.7×10\^6 or 4×10\^7 ADSCs in 3 mL saline. (allogeneic injection)
Study NCT03943576 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA
Description: Hya Joint Plus synovial fluid supplement 3mL
Study NCT03202433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of virtual reality lenses, with relaxing audio-visual contents
Description: Use of virtual reality lenses (and audio) as a distraction for the blood donor patients.
Study NCT04458246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training group
Description: Online aerobic home-based exercise training, 3 times per week, during 3 months. The exercise program is composed by 3 levels (starter, intermediate and advanced) which be completed in the first, second and third month of intervention, respectively.
Study NCT04619290 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control patients
Description: Control patients will be received the conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.
Study NCT02140645 — intervention group
Intervention type: DRUG
Intervention: linagliptin
Description: non-randomized
Study NCT03562884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI800
Description: Two bottles of BLI800 are needed for appropriate cleansing of the bowel. Prior to administration, the content of each bottle must be diluted in water, using the cup provided, to a total volume of approximately 0.5 L, and must be followed by the ingestion of 1 additional litre of water.
Study NCT03562884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fortrans®
Description: Fortrans® (Powder for Oral Solution) will be given according to Chinese approved Summary of Product Characteristics (SmPC). Fortrans® is provided as a powder for Polyethylene Glycol (PEG) based solution available in sachets containing a white powder readily miscible with water. The dosing for Fortrans® administration will be adapted to subjects' body weight as following: 1 L of solution for 15 to 20 kg, an average of 3 to 4 L (maximum 4 L).
Study NCT03643900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pancreatic duct stenting
Description: Place the pancreatic duct stent
Study NCT03643900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rectal indomethacin
Description: rectal indomethacin 100mg at preoperative 30min
Study NCT03643900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rectal indomethacin
Description: rectal indomethacin 100mg at preoperative 30min
Study NCT02480205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroBox to deliver the NeuroPAP
Description: The patients will be studied during the following conditions:~* On conventional NIPPV device with the clinically prescribed settings (30 min)~* With NeuroPAP and no change of Pmin (=peep) (60 min)~* With NeuroPAP and adjusted Pmin (decreased by 2 cmH2O) (60 min)~* During CPAP delivered with NeuroPAP device (15 min)~* Again with original NIPPV device and settings for 30 minutes
Study NCT00531596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMSAM (Selegiline Transdermal System) 6mg/24Hr
Description: EMSAM 6mg/24HR
Study NCT04241146 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enteric Tube
Description: A post pyloric feeding tube used in patients requiring enteral nutrition
Study NCT04241146 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CORTRAK enteral access system
Description: Electromagnetic guidance system for enteric feeding tube placement
Study NCT02181985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full dose TNK-tPA
Study NCT02181985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Full dose TNK-tPA
Study NCT02181985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Half dose TNK-tPA
Study NCT04384471 — intervention group
Intervention type: OTHER
Intervention: Online survey
Description: Participants are invited to answer an online questionnaire including both close-ended and open-ended questions about their experience during this sanitary crisis
Study NCT02181985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Study NCT02181985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Study NCT02181985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Study NCT02181985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Study NCT03104985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASMIK
Description: the physiotherapeutic device LASMIK (Registration Certificate in Russia № RZN 2015/2687 dated 25.05.2015).
Study NCT03104985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: * An elastic compression of lower extremities,~* Pharmacotherapy,~* Topical treatment
Study NCT03104985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: * An elastic compression of lower extremities,~* Pharmacotherapy,~* Topical treatment
Study NCT02876679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: GVHD prophylaxis: All patients will receive post-transplant 50mg/Kg/day cyclophosphamide (day +3 and +4) AND cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil in case of an HLA-matched unrelated donor
Study NCT02876679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulin
Description: GVHD prophylaxis: 2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1) All patients will receive cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil (MMF) in case of an HLA-matched unrelated donor.
Study NCT02038907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection
Study NCT02876679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conditioning regimen
Description: 30 mg/m2/day fludarabine for 5 days (day-6 to day-2) 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
Study NCT02876679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning regimen
Description: 30 mg/m2/day fludarabine for 5 days (day-6 to day-2) 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
Study NCT00842361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: The insulin NN5401 (insulin degludec/insulin aspart) injected subcutaneously immediately before breakfast and dinner.
Study NCT00842361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: The insulin (biphasic insulin aspart 30) injected subcutaneously immediately before breakfast and dinner.
Study NCT02481063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 3 Consecutive Days Running at 80% Maximus Heart Rate
Study NCT02481063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric Overload
Description: Training with Eccentric Overload (Squat in Yoyo Technology) during 6 Weeks 3 Consecutive Days Running at 80% Maximus Heart Rate
Study NCT02219997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clear clip-on glasses
Description: Clip-on glasses with no blue light filtering properties used as a placebo
Study NCT02219997 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear clip-on glasses
Description: Clip-on glasses with no blue light filtering properties used as a placebo
Study NCT02219997 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blue light filter clip-on glasses
Description: Clip-on glasses with blue light filtering properties similar to ACRYSOF® IOLs
Study NCT02219997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF® IQ IOL
Description: AcrySof IQ Aspheric Natural IOL Model SN60WF with UV and blue light filtering properties, previously implanted
Study NCT02219997 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear IOL
Description: Clear IOL, previously implanted
Study NCT01432093 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive glycemic management
Description: Intravenous insulin infusion, strict dietary intervention, carbohydrate matched subcutaneous insulin therapy. This is a multifaceted approach to achieve strict glucose goals of 90 to 120 mg/dL in the ICU and hospital wards.
Study NCT01432093 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional management
Description: Conventional treatment to control hyperglycemia with a target glucose goal of 120 to 150 mg/dL in the ICU and 140 to 180 mg/dL on the hospital floors.
Study NCT04907318 — intervention group
Intervention type: DEVICE
Intervention: Cataract surgery
Study NCT04270487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IBS Diet
Description: Patients will be randomized to a diet or a mediation treatment
Study NCT04270487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Otilonium Bromide
Description: Patients will be randomized to a diet or a mediation treatment
Study NCT05366257 — intervention group
Intervention type: OTHER
Intervention: CAR-T
Description: infusion of CAR-T therapy among patients with r/r DLBCL
Study NCT05366257 — intervention group
Intervention type: OTHER
Intervention: Allo-HSCT cohort
Description: Patients received allogeneic hematopoietic stem cell transplant
Study NCT03895970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus Pembrolizumab
Description: Lenvatinib 12mg, once a day, oral at least 38 days of each 6 weeks cycle. Pembrolizumab 200mg, every 3 weeks, intravenous infused of each 6 weeks cycle. Number of cycle: until progression or unacceptable toxicity develops.
Study NCT02988401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: All patients will receive either insulin or placebo using the Vianase III N2B device during the first 24 weeks of the study.
Study NCT02988401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sterile diluent)
Description: All patients will receive either insulin or placebo using Vianase III N2B device during the first 24 weeks of the study.
Study NCT03404518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norco
Description: Hydrocodone/Acetaminophen as first line therapy every 6 hours as needed for pain control
Study NCT03404518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen as first line therapy every 6 hours as needed for pain control
Study NCT02406053 — intervention group
Intervention type: GENETIC
Intervention: oxidative and antioxidant biomarkers
Description: the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.
Study NCT04285853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 5 mg oxycodone pills every 4-6 hrs if pain level 7 or higher on Numeric rating scale 1-10
Study NCT04285853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo tablets (both trial and rescue) will be matched to size, shape, color, and texture of oxycodone tablets.
Study NCT02376491 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Study NCT02376491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Study NCT00166517 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: 3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
Study NCT00166517 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: 3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
Study NCT00065442 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sipuleucel-T
Description: Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with a PAP-GM-CSF. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
Study NCT00065442 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: APC-Placebo
Description: Each dose of APC-Placebo contains approximately one-third of the quiescent APCs prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
Study NCT04451317 — intervention group
Intervention type: OTHER
Intervention: Questionnaire, phone call
Description: phone call and 3 questionnaires on a digital platform
Study NCT00934011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C-reactive protein guided antibiotic therapy
Description: plasma CRP measurement to guide the duration of antibiotic therapy
Study NCT00934011 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Procalcitonin guided antibiotic therapy
Description: plasma PCT measurement to guide the duration of antibiotic therapy
Study NCT02924818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical assessment
Study NCT03623698 — intervention group
Intervention type: DRUG
Intervention: Nebulised hypertonic saline
Description: Nebulised hypertonic saline used for a period of at least 12 months
Study NCT03432494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcaval closure device (TCD)
Description: Transcaval access and closure using the Transmural Transcaval Closure Device (TCD) at the time of medically-necessary transcatheter aortic valve replacement (TAVR).
Study NCT05412264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Website intervention
Description: 12 week motivational emails, recording pedometer steps and waist circumference
Study NCT02924818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Study NCT02654496 — intervention group
Intervention type: OTHER
Intervention: Meal challenge
Description: Participants will receive a liquid nutritional supplement. Before and after administration, biological variables of interest will be collected.
Study NCT00644943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefdinir (Omnicef)
Description: oral suspension (7 mg/kg, ql2hr) for 5 days
Study NCT00644943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin
Description: oral suspension (45 mg/kg/day, q l2 hours) for 10 days
Study NCT00531596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMSAM (Selegiline Transdermal System) 9mg/24Hr
Description: EMSAM 9mg/24Hr
Study NCT00531596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMSAM (Selegiline Transdermal System) 12mg/24hr
Description: EMSAM 12mg/24Hr
Study NCT00912574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF-in-adjuvant
Description: For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant
Study NCT00912574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montanide ISA-51
Description: For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant
Study NCT02924818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary function test
Study NCT00912574 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF and Montanide ISA-51
Description: For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant
Study NCT00912574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant
Study NCT04202185 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Retrospective collection data from diagnostic Data collected following to medical exam as part of care
Study NCT01309932 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Lambda (pegIFNλ)
Description: Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 or 48 weeks depending on response
Study NCT02924818 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood test
Study NCT02924818 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microbiology
Study NCT02924818 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: histology
Study NCT02924818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: imaging
Study NCT02608138 — intervention group
Intervention type: OTHER
Intervention: Iodine status among portuguese school children
Study NCT02846805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant-retained overdentures
Description: subjects will receive two-implant-retained overdentures in the mandible,and they continue wearing their complete denture in the maxilla.